Wall Street brokerages expect Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) to report earnings of ($0.16) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Invivo Therapeutics’ earnings. Invivo Therapeutics posted earnings of ($0.21) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 23.8%. The firm is scheduled to announce its next quarterly earnings results on Friday, March 9th.
On average, analysts expect that Invivo Therapeutics will report full-year earnings of ($0.81) per share for the current financial year, with EPS estimates ranging from ($0.83) to ($0.79). For the next financial year, analysts forecast that the company will report earnings of ($0.74) per share, with EPS estimates ranging from ($0.87) to ($0.61). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Invivo Therapeutics.
Invivo Therapeutics (NASDAQ:NVIV) last released its quarterly earnings data on Monday, October 30th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06).
Invivo Therapeutics (NASDAQ:NVIV) traded down $0.03 during trading hours on Friday, hitting $0.74. The stock had a trading volume of 281,206 shares, compared to its average volume of 301,270. The stock has a market capitalization of $24.30, a price-to-earnings ratio of -0.87 and a beta of 3.21. Invivo Therapeutics has a 52-week low of $0.60 and a 52-week high of $4.95. The company has a debt-to-equity ratio of 0.04, a quick ratio of 5.06 and a current ratio of 5.06.
Several large investors have recently added to or reduced their stakes in NVIV. Legal & General Group Plc boosted its stake in shares of Invivo Therapeutics by 4,427.9% during the second quarter. Legal & General Group Plc now owns 503,407 shares of the biotechnology company’s stock valued at $1,359,000 after purchasing an additional 492,289 shares during the period. Blair William & Co. IL purchased a new stake in shares of Invivo Therapeutics during the second quarter valued at approximately $159,000. Goldman Sachs Group Inc. boosted its stake in shares of Invivo Therapeutics by 144.5% during the second quarter. Goldman Sachs Group Inc. now owns 167,318 shares of the biotechnology company’s stock valued at $452,000 after purchasing an additional 98,879 shares during the period. Finally, Susquehanna International Group LLP purchased a new stake in shares of Invivo Therapeutics during the second quarter valued at approximately $434,000. 12.84% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/0-16-eps-expected-for-invivo-therapeutics-holdings-corp-nviv-this-quarter.html.
About Invivo Therapeutics
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.
Get a free copy of the Zacks research report on Invivo Therapeutics (NVIV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.